Innovative Industrial Properties earnings date
Innovative Industrial Properties (1IK) Q3 2026 Earnings Report
DE:1IK Q3 2026 EPS Results
- Actual EPS
- EUR 0.89
- Consensus EPS
- EUR 0.81
- Beat/Miss
- Beat by +EUR 0.08
- One Year Ago EPS
- EUR 0.87
DE:1IK Q3 2026 Revenue Results
- Actual Revenue
- EUR 58.50M
- Expected Revenue
- EUR 55.00M
- Beat/Miss
- Beat by +EUR 3.51M
- YoY Revenue Growth
- +0.36%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/02/2026
- Time
- After Close
- Conference Call
- Monday, November 2, 2026
Innovative Industrial Properties's next earnings date is estimated for March 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive. Highlights significantly outweighed lowlights, supported by 7% sequential AFFO per-share growth, record leasing activity, substantial life science investment commitments, improving life science demand, strong liquidity, and low leverage. The main challenges were persistent financial stress among some cannabis operators, remaining vacancy, potentially lengthy re-leasing timelines, uncertainty around federal reform, and the presence of nonrecurring items in quarterly AFFO.
Management said it “do[es] not give guidance” on whether quarterly AFFO will remain above the $1.90 payout. Re-leasing previously vacated properties has historically taken “anywhere from 6 to 18 months” from sourcing a new tenant through lease commencement, license transfer, and the regulatory process; remaining vacancy is “a little over 800 thousand square feet,” with “2-thirds” in the 2 Florida assets previously leased to Parallel. The $245 million Alewife Park mezzanine loan commitment funded approximately $111 million at closing, with the remaining $134 million “expected to be funded through the fourth quarter of 2027” at an average interest rate of “~15.8%,” and life science investments are “projected to account for ~26% of our total annualized income.” An additional $155 million IQHQ opportunity “is a possibility” subject to access to capital and capital-allocation decisions, while 446 thousand square feet of additional leasing agreements remain subject to customary due diligence, licensing, and regulatory approvals.
- AFFO and Revenue GrowthThird-quarter total revenues increased to $64.9 million from $63.3 million in the second quarter. AFFO rose 7% sequentially to $54.8 million, or $1.96 per diluted share, from $53.0 million, or $1.83 per diluted share. The increase was driven by new leases and recoveries of past-due rents, primarily from Battle Green, which contributed $0.15 per share.
- Significant Life Science Investment ExpansionThe company closed on $275 million of new life science commitments during the quarter, including an additional $30 million IQHQ preferred equity investment and a $245 million mezzanine loan commitment for Alewife Park in Cambridge, Massachusetts. Including the original $270 million IQHQ commitment, total life science commitments reached approximately $545 million.
- Attractive Alewife Park Loan EconomicsThe $245 million Alewife Park mezzanine loan is expected to generate an average interest rate of approximately 15.8% over its term. Approximately $111 million was funded at closing, with the remaining $134 million expected to be funded through the fourth quarter of 2027.
- Alewife Park Asset Quality and LeasingAlewife Park is a 27-acre campus with three existing buildings totaling 392,000 square feet and two pad-ready sites with up to 364,000 square feet of additional development potential. The existing buildings are 78% leased to Lila Sciences, and the financing will support tenant improvements, lease-up, and stabilization.
- Life Science Investments Increasing Portfolio DiversificationUpon full funding, life science investments are projected to account for approximately 26% of total annualized income. Management said the diversification has increased access to new lenders and capital sources and is intended to reduce the company's focus on a cannabis-only portfolio.
- Record Quarterly Leasing ActivityThe company executed new leases totaling approximately 604,000 square feet across six properties during the third quarter, followed by an additional 270,000-square-foot lease after quarter end. Total leasing activity since the beginning of the third quarter reached approximately 874,000 square feet.
- Year-to-Date Leasing MomentumYear-to-date gross leasing activity reached approximately 1.3 million square feet across 12 properties, representing 15% of the total portfolio. Management said it continues to see strong interest across the portfolio and has an active pipeline of additional transactions.
- Additional Leasing PipelineThe company has agreements covering three Colorado properties totaling 72,000 square feet, subject to license transfer and regulatory approval, plus agreements covering three properties previously leased to 4Front Ventures totaling 374,000 square feet. Together, these agreements represent an additional 446,000 square feet beyond leases already executed.
- Improving Life Science Market DemandAccording to JLL, combined demand in Boston, San Diego, the Bay Area, and Raleigh-Durham increased 44% year over year to nearly 8 million square feet in the first quarter of 2026, driven by improved biotech funding conditions and biomanufacturing reshoring.
- Access to Preferred Equity CapitalSubsequent to quarter end, the company completed a public offering of 2.2 million shares of 9.25% Series B preferred stock at $25.00 per share, generating $54 million in gross proceeds. The proceeds are intended to fund all or part of the remaining Alewife Park mezzanine loan commitment and general corporate purposes.
- Strong Liquidity and Conservative LeverageThe company ended the quarter with $142 million in total liquidity, excluding the recent $50 million preferred raise, net debt to adjusted EBITDA of 2.1x, and net debt to total gross assets of 19%. Management described the capital structure and liquidity position as conservative.
- Revolving Credit Facility ExtensionSubsequent to quarter end, the company executed a 90-day extension of its existing $87.5 million revolving credit facility, extending its maturity to January 2027. Management said the extension provides additional flexibility to evaluate financing alternatives and manage the capital structure.
- Expanded Equity Research CoverageStifel Nicolaus and Huntington Capital Markets began covering the company, bringing total equity research coverage to eight firms.
- Cannabis Market and Regulatory DevelopmentsThe DEA completed its hearing on the proposed rescheduling of marijuana from Schedule I to Schedule III. Management said reform could provide improved economics and broader access to traditional capital sources, while also noting that the timing and outcome remain uncertain. Florida approved 22 additional vertically integrated medical cannabis licenses.
- Cannabis Industry Sales MilestonesMassachusetts surpassed $10 billion in cumulative adult-use cannabis sales in September, while California generated nearly $8.4 billion in cannabis tax revenue since 2018.
- Portfolio Re-Tenanting ExecutionThe company regained possession of properties previously leased to Parallel, PharmCann, and The Cannabis Company and said these transitions allow it to pursue new leasing opportunities and strengthen its tenant base. New leases have already been executed for certain terminated properties, including a Battle Green property in New York and a 4Front property in Washington.
- Capital-Efficient Re-TenantingManagement said year-to-date re-tenanting costs were well below $10 per square foot, including commissions, tenant improvements, landlord work, and other costs.
DE:1IK Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 01, 2027 | 2026 (Q4) | 0.83- | 0.96 | ― | ― |
| Nov 02, 2026 | 2026 (Q3) | 0.810.89 | 0.87 | 2.06% (+0.02) | |
| Aug 03, 2026 | 2026 (Q2) | 0.921.23 | 0.78 | 58.14% (+0.45) | |
| May 04, 2026 | 2026 (Q1) | 0.970.92 | 0.93 | -0.97% (-0.01) | |
| Feb 23, 2026 | 2025 (Q4) | 0.940.96 | 1.23 | -22.06% (-0.27) | |
| Nov 03, 2025 | 2025 (Q3) | 0.810.87 | 1.23 | -29.20% (-0.36) | |
| Aug 06, 2025 | 2025 (Q2) | 0.820.78 | 1.3 | -40.28% (-0.52) | |
| May 07, 2025 | 2025 (Q1) | 1.030.93 | 1.23 | -24.26% (-0.30) | |
| Feb 19, 2025 | 2024 (Q4) | 1.231.23 | 1.31 | -6.21% (-0.08) | |
| Nov 06, 2024 | 2024 (Q3) | 1.301.23 | 1.31 | -5.52% (-0.07) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


